-
Validation of an Artificial Intelligence-Based Prognostic Biomarker in Patients with Oligometastatic Castration-Sensitive Prostate Cancer - Beyond the Abstract
22 Jan 2025 23:00 GMT
… mutations.
For oligometastatic castration-sensitive prostate cancer (omCSPC), an intermediate state between … patients (n=222) from Johns Hopkins Hospital and Ghent Hospital who … Philip Sutera,13 Piet Ost14
Johns Hopkins University, Baltimore, MD, USA.
…
-
Intratumoral Heterogeneity Drives Acquired Therapy Resistance in a Patient with Metastatic Prostate Cancer - Beyond the Abstract
22 Jan 2025 23:00 GMT
… therapies to treat prostate cancer, metastatic disease is … heterogeneity, with primary prostate cancer often being multifocal … a patient with metastatic prostate cancer.
Written by: Dena … Comprehensive Cancer Center at Johns Hopkins
References:
Rhinehart, Dena …
-
PSMA+ Extracellular Vesicles are a Biomarker for SABR in Oligorecurrent Prostate Cancer Analysis from the STOMP-like and ORIOLE trial cohorts.
21 Jan 2025 08:35 GMT
… patients with metachronous oligometastatic prostate cancer (omCSPC) patients. While … ., Ghent University, Belgium., Johns Hopkins Hospital, Baltimore, Maryland, … States., Johns Hopkins University, Baltimore, Maryland, United States., Johns Hopkins University, …
-
Personalized Dynamic Prediction Model for Biopsy Timing in Patients With Prostate Cancer During Active Surveillance.
21 Jan 2025 08:35 GMT
… using data from the Prostate Cancer Research International: Active Surveillance … , the Global Action Plan Prostate Cancer Active Surveillance initiative database. … James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, Maryland., King …
-
Incidental discovery of gastrointestinal stromal tumor via PSMA-PET/CT imaging: Insights from a case report.
28 Jan 2025 12:25 GMT
… a superior diagnostic tool for prostate cancer, demonstrating enhanced accuracy over conventional … for detecting local and metastatic prostate tumors, it can also identify … Center, The Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, …
-
Retiring Shouldn’t Mean Resigning: The Power of Speaking Up About Your Advanced Prostate Cancer Treatment Options
08 Jan 2025 21:53 GMT
… metastatic castration-resistant prostate cancer (mCRPC), it … metastatic castration-resistant prostate cancer (PSMA-positive … .html
2. Johns Hopkins Medicine. Prostate cancer prognosis. Accessed … -diseases/prostate-cancer/prostate-cancer-prognosis
3. …
-
Johns Hopkins, Howard University team to improve cancer care
08 Jan 2025 08:38 GMT
… has been dubbed The Howard-Johns Hopkins Comprehensive Alliance in Cancer Research … to examine the drivers of prostate cancer in Black men.
Black Americans … to train at Howard and Johns Hopkins.”
Johns Hopkins and Howard University partnered for …
-
Johns Hopkins, Howard University Team Up to Advance Health Equity
08 Jan 2025 02:51 GMT
… Cancer Center.
The Howard-Johns Hopkins Comprehensive Alliance in Cancer Research … molecular epigenetic drivers of aggressive prostate cancer among African American men. … Academic Research Experience at The Johns Hopkins University, the extensive research …
-
Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and Without DNA Repair Defects - Beyond the Abstract
07 Jan 2025 23:40 GMT
… success in metastatic castration-resistant prostate cancer (mCRPC). DNA repair defects (DRDs … , LACOG GU, Adjunct Assistant Professor, Johns Hopkins University, Baltimore, MD
Read the …
-
Many older men with prostate cancer and limited life expectancy are overtreated
06 Jan 2025 10:50 GMT
… and certain localized prostate cancers have received definitive … Daskivich said.
Consequently, prostate cancer guidelines have recommended against … of medicine at Johns Hopkins University School of … The likelihood of prostate cancer progressing to symptomatic …
About
© 1995-2025